Pharmacogenomic analysis has become a critical part of Pfizer's drug development efforts, that Jean-Claude Marshall calls an "insurance policy" well worth the investment.
SeraCare is licensing UCSF's T21, T18, and T13 trophoblast cell line materials to develop NIPT reference materials.
Shuwen Biotech will develop, manufacture, and market a test for a Hengrui cancer drug, as well as screen patients with the test for upcoming clinical trials.
The NGS panel looks for mutations in KRAS, BRAF, EGFR, ROS1, and ALK and will be available through Admera's sales partner Rosetta Genomics.
Under the terms of the pact, the partners will integrate Translational's pharmacogenetics knowledgebase and interpretation platform with Xifin's laboratory information system.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.